Trial · NCT01247220
REtinal Vein OccLUsion Treatment With Scatter Laser Guided by UWFA in combiNAtion With Ranibizumab Study
NCT01247220, Phase 2, Completed, Retina Associates of Florida, P.A.; results first posted 2014-10-06
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. REtinal Vein OccLUsion Treatment With Scatter Laser Guided by UWFA in combiNAtion With Ranibizumab Study. Trials, record NCT01247220. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT01247220
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- REtinal Vein OccLUsion Treatment With Scatter Laser Guided by UWFA in combiNAtion With Ranibizumab Study
- NCT number
- NCT01247220
- Status
- Completed
- Phases
- Phase 2
- Enrollment
- 12 participants, actual
- Lead sponsor
- Retina Associates of Florida, P.A.
- Conditions
- Macular Edema, Branch Retinal Vein Occlusion
- Interventions
- Ranibizumab, Peripheral Laser
- First posted
- 2010-11-24
- Last updated
- 2014-10-06
- Results first posted
- 2014-10-06
- Limitations and caveats
- small study size
Source ClinicalTrials.gov
Registered outcomes3
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Visual Acuity | 6 and 12 months | ETDRS visual acuity |
| Secondary | Number of Ranibizumab Injections | 12 months | Number of ranibizumab injections needed by decreased visual acuity and/or increasing retinal thickness in second six months of observation period |
| Secondary | Retinal Thickness | 6 and 12 months | central foveal thickness on optical coherence tomography |
Source ClinicalTrials.gov
Outcomes3
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Visual Acuity | 6 and 12 months | letters on ETDRS Visual Acuity Chart | MEAN | |
| SECONDARY | Number of Ranibizumab Injections | 12 months | injections | MEAN | |
| SECONDARY | Retinal Thickness | 6 and 12 months | microns | MEAN |
Source ClinicalTrials.gov
Results by group10
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Visual Acuity | Peripheral Laser + Ranibizumab | 6 month results | 16.8 | Standard Deviation 10.1 | letters on ETDRS Visual Acuity Chart |
| Visual Acuity | Ranibizumab | 6 month results | 14.5 | Standard Deviation 11.6 | letters on ETDRS Visual Acuity Chart |
| Visual Acuity | Peripheral Laser + Ranibizumab | 12 month results | 19.1 | Standard Deviation 7.4 | letters on ETDRS Visual Acuity Chart |
| Visual Acuity | Ranibizumab | 12 month results | 15.3 | Standard Deviation 13.2 | letters on ETDRS Visual Acuity Chart |
| Number of Ranibizumab Injections | Peripheral Laser + Ranibizumab | 0.06 | Full Range 0 to 1 | injections | |
| Number of Ranibizumab Injections | Ranibizumab | 2.2 | Full Range 1 to 4 | injections | |
| Retinal Thickness | Peripheral Laser + Ranibizumab | 6 month results | 207 | Standard Deviation 47 | microns |
| Retinal Thickness | Ranibizumab | 6 month results | 241 | Standard Deviation 45 | microns |
| Retinal Thickness | Peripheral Laser + Ranibizumab | 12 month results | 282 | Standard Deviation 26 | microns |
| Retinal Thickness | Ranibizumab | 12 month results | 281 | Standard Deviation 29 | microns |
Source ClinicalTrials.gov
Participant flow6
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Peripheral Laser + Ranibizumab | 6 | |
| Overall Study | STARTED | Ranibizumab | 6 | |
| Overall Study | COMPLETED | Peripheral Laser + Ranibizumab | 6 | |
| Overall Study | COMPLETED | Ranibizumab | 6 | |
| Overall Study | NOT COMPLETED | Peripheral Laser + Ranibizumab | 0 | |
| Overall Study | NOT COMPLETED | Ranibizumab | 0 |
Source ClinicalTrials.gov
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals6
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Peripheral Laser + Ranibizumab | ||
| Total, all-cause mortality | Ranibizumab | ||
| Total, other adverse events | Peripheral Laser + Ranibizumab | 0 | 6 |
| Total, other adverse events | Ranibizumab | 0 | 6 |
| Total, serious adverse events | Peripheral Laser + Ranibizumab | 0 | 6 |
| Total, serious adverse events | Ranibizumab | 0 | 6 |
Source ClinicalTrials.gov
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons1
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison |
|---|
| Peripheral Laser + Ranibizumab vs Ranibizumab: serious adverse events |
Source Trial comparisons
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT01247220
GET https://conductscience.org/api/trials/v1/NCT01247220/registered